CM336

CM336 is a BCMA/CD3 bispecific antibody from Chinese biotech Keymed Biosciences, running in four active Phase 2 trials and one Phase 1 trial: multiple myeloma with severe renal impairment, AL amyloidosis (newly diagnosed and relapsed), autoimmune bullous disease (all Phase 2), and relapsed/refractory autoimmune cytopenia (Phase 1) [1][2][3][4][5]. The drug copies a mechanism already validated by three FDA-approved BCMAxCD3 bispecifics: teclistamab (J&J), elranatamab (Pfizer), and linvoseltamab (Regeneron) [6][7][8]. Keymed's strategy splits the playbook: instead of chasing relapsed/refractory multiple myeloma where the approved drugs dominate, CM336 targets adjacent plasma-cell-driven diseases where no bispecific has been approved. NCT07151690, the trial referenced here, tests CM336 in newly diagnosed light-chain amyloidosis, an indication where the current standard, daratumumab plus CyBorD (cyclophosphamide, bortezomib, dexamethasone), achieves roughly 78 percent VGPR or better but still leaves meaningful unmet need around organ response and durability [12].

Novel compound, lead indication in Phase 2. Five concurrent trials are open, all in China (four Phase 2, one Phase 1) [1][2][3][4][5]. Keymed sponsors the autoimmune cytopenia and the n=90 AL amyloidosis efficacy studies directly; the Institute of Hematology & Blood Diseases Hospital in Tianjin runs the MM-renal study, the AL amyloidosis NCT07151690 study, and is involved in autoimmune bullous work via Shandong First Medical University. No FDA Breakthrough, Fast Track, Orphan Drug, or RMAT designations have been disclosed, consistent with a program that has not yet engaged the U.S. regulatory process. CM336 has not been submitted to the FDA or EMA based on publicly available filings, and no IND in a non-China jurisdiction has been disclosed. CM336 Phase 1/2 data in relapsed/refractory multiple myeloma was published in NEJM in 2025 [15], so safety and efficacy are no longer black-box; that readout supports the Phase 2 expansion across indications. The amyloidosis trial NCT07151690 targets only 21 patients with hematologic VGPR as the primary endpoint, a small proof-of-concept readout rather than registrational evidence [3]. A public expected-readout date is not disclosed, but single-arm Phase 2 trials of this size typically post initial data 12 to 24 months after opening. China's NMPA (National Medical Products Administration) pathway is the likely first regulatory step; global development would require a partnership or licensing deal.

BCMA stands for B-cell maturation antigen. It is a protein that sits on the surface of plasma cells, the antibody-producing factories at the end of B-cell development. In multiple myeloma and AL amyloidosis, plasma cells go rogue: in myeloma they overgrow and crowd out the bone marrow; in amyloidosis they pump out misfolded light chains that deposit in organs (heart, kidney, nerves) and cause organ failure [9]. Either way, killing the bad plasma cells is the therapeutic goal. CM336 is a bispecific antibody, meaning one molecule with two grabbing arms: one arm latches onto BCMA on the plasma cell, the other arm grabs CD3 on a T cell. The drug physically pulls T cells next to plasma cells and triggers killing. This mechanism has been validated three times over. Teclistamab, elranatamab, and linvoseltamab all run the same playbook in relapsed/refractory multiple myeloma and produce overall response rates of roughly 60 to 70 percent in heavily pretreated patients [6][10]. CM336's own Phase 1/2 dose-escalation in RRMM (n=25 as of June 2024) showed a confirmed ORR of 60.9 percent at 8-month median follow-up, putting it in the same response range as the approved competitors [15]. The open question for CM336 is whether the mechanism transfers cleanly to AL amyloidosis, where plasma cell burden is typically lower but organ vulnerability is much higher.

NCT07151690 is a Phase 2 single-arm open-label study in newly diagnosed AL amyloidosis, sponsored by the Institute of Hematology & Blood Diseases Hospital in Tianjin, target enrollment 21 patients [3]. The primary endpoint is the rate of hematologic VGPR (Very Good Partial Response) or better, measured by reduction in serum free light chain levels. VGPR is the standard surrogate in AL amyloidosis because organ response lags hematologic response by months. The relevant benchmark is ANDROMEDA: daratumumab plus CyBorD (cyclophosphamide, bortezomib, and dexamethasone, a three-drug chemotherapy backbone) delivered VGPR or better in approximately 78 percent of newly diagnosed AL patients versus 49 percent with CyBorD alone [12]. CM336 would need to approach or exceed the ~78 percent dara-CyBorD bar to displace the current standard, not the 49 percent control bar. Twenty-one patients is statistically thin: it can rule in a strong signal but cannot rule out modest improvement, and there is no comparator arm. The companion Keymed-sponsored trial NCT07039578 is the more credible registrational vehicle: open-label Phase 2, target enrollment 90 patients, sponsored directly by Keymed in newly diagnosed and relapsed/refractory AL amyloidosis, with hematologic response as the primary endpoint [5]. A specific design concern: AL amyloidosis patients with cardiac involvement (roughly 70 percent of cases) tolerate cytokine release syndrome poorly because their cardiac reserve is already compromised. Whether the protocol excludes high-stage cardiac AL is not publicly clear, and that exclusion criterion will shape both safety and how generalizable the data are. Real-world context for China: daratumumab is approved in China for AL amyloidosis (NMPA approval 2023) but uptake and reimbursement at the newly diagnosed line are uneven, so the practical comparator for CM336 in many Chinese centers is still bortezomib-based therapy without daratumumab. That widens the apparent benefit at home but narrows it for any OUS expansion.

Our model estimates a 18% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 34%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by a non-randomized design; it is held back by the sponsor's thin or weak approval record, weak or limited earlier-phase results, and smaller-than-typical enrollment for this phase. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Safety: cytokine release syndrome is the dominant on-target risk across all BCMAxCD3 bispecifics. Teclistamab reported Grade 1-2 CRS in roughly 70 percent of patients in MajesTEC-1, mostly manageable, but Grade 3 events do occur [10]. CM336's own Phase 1/2 in RRMM showed any-grade CRS in 68 percent of patients with only one Grade ≥3 event in 25 subjects, all CRS events resolved completely, and no ICANS reported [15] - a profile in line with the class but importantly not generated in AL amyloidosis patients, where cardiac amyloid deposits and impaired cardiac reserve make fluid shifts triggered by CRS potentially lethal. The class also drives sustained B-cell depletion, raising infection risk; the teclistamab label carries warnings for hypogammaglobulinemia and opportunistic infections [6]. Efficacy: AL amyloidosis outcomes depend on organ recovery, not just hematologic response, and organ response is unpredictable in advanced cardiac-stage patients. Execution: NCT07151690 is a 21-patient single-arm trial, too small to support standalone approval in any major market. Commercial: even if data come in positive, Keymed Biosciences has no commercial infrastructure outside China. The path to U.S. and EU patients runs through a partnership that has not been announced for CM336 specifically. Three approved BCMAxCD3 bispecifics are already on the market, and investigator-initiated studies of teclistamab in AL amyloidosis are reportedly underway, creating direct competition for positioning if CM336 ever expands beyond China.

Worth tracking, signal is moderate. CM336 is a credible mechanism (BCMAxCD3 works, and CM336's own NEJM-published Phase 1/2 confirms it works in their hands [15]), pursued in a sensible indication (AL amyloidosis has real unmet need after daratumumab), by a sponsor with limited Western visibility. Five concurrent trials suggest an aggressive pace, with five potential readouts in the next 18 to 24 months [1][2][3][4][5]. Two signals that would convert this from noise to actionable: (1) an interim VGPR rate approaching the ~78 percent dara-CyBorD bar in NCT07039578 (the n=90 Keymed-sponsored AL amyloidosis study, more interpretable than the n=21 academic study) [5], and (2) any U.S. or European licensing announcement for CM336 specifically. Check back end of 2026 or first half of 2027 for both. Financial context: Keymed (HKEX 2162) reported approximately RMB 1.96 billion in cash at year-end 2025, raised an additional HK$864 million in 2025 placements, and is expected to receive ~US$250 million upfront from Gilead's acquisition of partner Ouro Medicines (which licensed Keymed's BCMAxCD3 autoimmune program OM336) [16][17]. Multi-year runway, so they are not forced into a bad CM336 deal to fund the program. Keymed has previously partnered the Claudin 18.2 ADC CMG901 with AstraZeneca [14], so they have shown they can execute Western deals at the right asset stage.